Innovating medicines
for breast cancer and beyond.
Innovating medicines
for breast cancer and beyond.
Innovating medicines
for breast cancer and beyond.
Pursuing better treatments to help patients feel better, longer.
Bring your passion, join our team and make your mark.
Olema's latest news and recent events.
-
April 25th, 2025 Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
-
April 2nd, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
March 25th, 2025 Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
-
March 18th, 2025 Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
-
March 4th, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
February 19th, 2025 Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
-
April 25th, 2025 Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
-
April 2nd, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
March 25th, 2025 Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
-
March 18th, 2025 Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
-
March 4th, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
February 19th, 2025 Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
Item 1 of 6